Further commentary in @RheumJnl from Peter Taylor – definitely a space to watchhttps://t.co/74St0w4DmS
— David Liew (@drdavidliew) June 16, 2019
It’s been a fantastic meeting – this is me, signing off from #EULAR2019 in Madrid! @RheumNow https://t.co/iYAcClaFMR pic.twitter.com/JQkXXNqdVN
— David Liew (@drdavidliew) June 15, 2019
That’s a wrap! Thank you to all delegates, speakers, submitters and exhibitors for making #EULAR2019 unforgettable! pic.twitter.com/RSa6DkCPt1
— EULAR (@eular_org) June 15, 2019
And off we go. Thank you #EULAR2019. Thank you #Madrid. What a beautiful city. We enjoyed seeing our friends on this side of the planet for a change. We look forward to Frankfurt 2020. Adiós! pic.twitter.com/vT8bURmkpJ
— J Rheum (@jrheum) June 16, 2019
Dr. Dinesh Khanna discusses the pulmonary outcomes of tocilizumab is systemic sclerosis (focuSSed trial). #EULAR2019 OP0245 pic.twitter.com/KvxoPhvyS6
— Dr. John Cush (@RheumNow) June 17, 2019
Presentation today at ATS #ATS2019. 1. early diffuse SSc. 2. 64% have ILD-recruited for elevated acute phase reactants. 3. treated with Tocilizumab vs. placebo for 48 wks EARLY SSc; elevated acute phase reactants; anti-IL-6 inhibition–> PRESERVATION OF ILD pic.twitter.com/63lwR1G0Cp
— Dr. Dinesh Khanna (@sclerodermaUM) May 20, 2019
Going beyond scleroderma. 1. Tanezumab is effective for OA related pain and no new safety concerns. #EULAR2019 pic.twitter.com/Uohex1uybS
— Dr. Dinesh Khanna (@sclerodermaUM) June 15, 2019
Low dose rituximab for retreatnent of RA. —6 month trial —RCT 1000 mg or 500 mg or 200 mg single dose. —there were more flares with low dose but less SI. — DAS 28 response was similar #EULAR2019
— Dr. Dinesh Khanna (@sclerodermaUM) June 15, 2019
Exercise program 30 min 12w (combination of generalised upper limb and specific hand exercises) helps to improve pain, function, dexterity, QOL over time more so than controlled group #eular2019 @RheumNow
— Alberta Hoi (@tuna0sashimi) June 14, 2019
MTX withdrawal in tofacitinib MR 11mg ORAL shift 1y study @week 24, MTX blindly withdrawal for pt achieved LDA (CDAI <=10) n>200 each arm no difference between arms consistent with anecdotal evidence of how pt can withdraw MTX in real life. #eular2019 @RheumNow
— Alberta Hoi (@tuna0sashimi) June 15, 2019
#eular2019 H2H abatacept vs adalimumab prev study “AMPLE” showed similar efficacy (single blinded RA <2y study). Now “Early AMPLE” study for seropositive RA with or without HLA shared epitope confirmed previous observation of superiority of ABA at 24w
— Alberta Hoi (@tuna0sashimi) June 15, 2019
— Mehreen (@MehreenSoomro) June 15, 2019
It is always an absolute privilege working with Iain
Looking forward to his stint as @eular_org President…his track record suggests there will be some innovations ahead!@Racegbn @iiiglasgow @UofGMVLS @imidbio https://t.co/932Iz9kayV
— Stefan Siebert (@StefanSiebert1) June 16, 2019
EULAR HIGHLIGHTS. Ixekizumab beats adalimumab in PsA on combined end pt of skin + joints due to high skin response #EULAR2019 @RheumNow
— Janet Pope (@Janetbirdope) June 16, 2019
EULAR Highlights. 2 new JAKs presented more RA data. Upadacitinib and Filgotinib. Safety of JAKs in meta-analysis -no new safety signals. Tofacitinib use in Corrona = TNFI except slightly more shingles. 7yr Baricitinib data good – no VTE in LTE #EULAR2019 @RheumNow
— Janet Pope (@Janetbirdope) June 16, 2019
A very productive Mentor Mentee meeting with the best mentors and best mentees @EMEUNET #EULAR19 #Madrid pic.twitter.com/nLQkdnK0u3
— EMEUNET (@EMEUNET) June 16, 2019
See @RheumILD! We love Ritux!
— Isabelle Amigues, MD, MS, RhMSUS, human, mom etc (@isa75012) June 16, 2019
Here's a 2 min snapshot of #physicalactivity uptake at #EULAR2019
➡️88% (23) used #escalator
➡️12% (3) used #stairs
➡️87% (20) on escalator stood still
➡️13% (3) walked on escalatorWell done all who used stairs!👍🏽
Good use of facilities & opportunitiespic.twitter.com/7NgdOBtc1z— Dr Ai Lyn Tan (@DrAiLynTan) June 17, 2019
RheumNow Podcast from EULAR19 is up! EULAR 2019 Streamin' (6.14.19). You can view it here>> https://t.co/fTdH4kuCJX or listen on iTunes or SoundCloud >> https://t.co/TGxUixKoIj
— Dr. John Cush (@RheumNow) June 17, 2019
#EULAR2019 commentary on RheumNow's meeting coverage site: https://t.co/5zpSSNXARC – hope you check it out. It features tweets, video interviews, articles and more. Our final meeting wrap up hits tomorrow. Hope everyone had safe travels home.
— Dr. John Cush (@RheumNow) June 16, 2019
Bad news. Chikungunya has arrived to Spain. The mosquito bites happened last May in Alicante.
Tres turistas islandeses en Alicante, primeros infectados de chikungunya en España https://t.co/v89dEVyFHr vía @el_pais— Emilio Martin Mola (@emartinmola) June 14, 2019
Major Unanswered Question: according to EULAR Recommendations a regular follow-up and monitoring of disease activity in patients with large vessels vasculitis is recommended
👉🏻But how often❓
👉🏻Is imaging useful at all❓
👉🏻How to screen for vessel stenosis & aneurysms❓#EULAR2019 pic.twitter.com/xFvq1qfIGN— Juan Ovalles, MD, PhD (@DrJuanOvalles) June 12, 2019
We unfortunately missed out on it at #EULAR2019 but nice work and important paper from @CCalabreseDO @cappelliMD @MarieKostine @BetsyKirch @LCalabreseDO on PMR-like irAEs. An area worth exploring! https://t.co/IrEI7QzCPZ @RheumNow
— David Liew (@drdavidliew) June 15, 2019
"My confidence & zest for life back again", "Being a good mum", "Not having to think about ways to conserve energy". The #patient view of #remission involves the symptoms of the disease, as well as its manifestations. Ruth Williams at #EULAR2019 pic.twitter.com/uzaF7lXuEg
— Arthritis Ireland (@Arthritisie) June 15, 2019
Some very good & practical suggestions for how to improve function and patient #remission suggested by Ruth Williams: good continuity of care & communication; holistic approach to physio, OT & podiatry; CBT; exercise classes & simple aids. #EULAR2019 pic.twitter.com/OHxLjV7Syj
— Arthritis Ireland (@Arthritisie) June 15, 2019